AUPH SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Aurinia Pharmaceuticals Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance

Oct 30, 2026

8-K

Aurinia Pharmaceuticals Settles Patent Litigation with Teva Regarding Voclosporin

Aug 19, 2026

8-K

Aurinia Pharmaceuticals Reports Q2 2026 Financial Results and Business Updates

Aug 6, 2026

8-K

Aurinia Pharmaceuticals Inc. Announces Results of 2026 Annual General Meeting

Jun 4, 2026

8-K

Acquisition Completed: Parent Company Acquires Kezar Life Sciences Through Tender Offer and Merger, Effective May 11, 2026.

May 11, 2026

8-K

Aurinia Pharmaceuticals Reports Q1 2026 Financial Results and Reaffirms Annual Guidance

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

May 11, 2026

SC TO-T

Form SC TO-T - Tender offer statement by Third Party

Apr 13, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 16, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 26, 2023

S-3ASR

$250,000,000 Common Shares PROSPECTUS Cantor November 19, 2021-

Nov 19, 2021

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 25, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 4, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 3, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Robertson Stephen P. (Reporting)

Sep 11, 2026

SCHEDULE 13D/A

ILJIN SNT Co., Ltd. (Filed by)

Aug 26, 2026

Robertson Stephen P. (Reporting)

Aug 25, 2026

144

Form 144 - Report of proposed sale of securities

Aug 21, 2026

Johnson Craig A (Reporting)

Jun 8, 2026

Goetz Kathleen (Reporting)

Jun 8, 2026

Other

TYPE

HEADLINE

FILED AT

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Jul 23, 2020

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Jul 22, 2020

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Jun 26, 2020

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 22, 2020

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Dec 10, 2019

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Dec 9, 2019

Aurinia Pharmaceuticals Inc. AUPH · SEC Filings